Questionnaire survey on proper use methods based on experience of using safinamide

Questionnaire survey on proper use methods based on experience of using safinamide - Questionnaire survey on proper use methods of safinamide

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043283

Enrollment

150

Registered

2021-02-17

Start date

2021-02-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects must satisfy all of the follwing criteria. [Selection criteria in the 1st Questionnaire Survey] 1)Doctors who fully understands the research and have consent to participate in this survey on the website. 2) Doctors over 30 years old 3) Doctors with more than 5 years of experience in treating Parkinson's disease 4) Doctors with 10 or more patients with Parkinson's disease who are continuously treated 5) Doctors with one or more patients who have prescribed safinamide [Selection criteria in the 2nd Questionnaire Survey] 1) Doctors who fully understands the research and have consent to participate in this survey on the website. 2) Doctors over 30 years old 3) Doctors with more than 5 years of experience in treating Parkinson's disease 4) Doctors with 10 or more patients with Parkinson's disease who are continuously treated 5) Doctors who have prescribed safinamide for 5 or more patients and have been using it for 3 months or more

Exclusion criteria

Exclusion criteria: [Exclusion criteria in the 1st Questionnaire Survey] 1) Doctors who cannot fill out and answer questionnaires by themselves 2) Doctors who did not complete the answers to all the questionnaires [Exclusion criteria in the 2nd Questionnaire Survey] 1) Doctors who cannot fill out and answer questionnaires by themselves 2) Doctors who did not complete the answers to all the questionnaires 3) Doctors who are judged by the principal investigator / coordinator to be inappropriate for the results of this study

Design outcomes

Primary

Measure	Time frame
The following items are evaluated on a four-point scale: 1 (disagree), 2 (somewhat disagree), 3 (somewhat agree), and 4 (agree). For some questions, the perspective of the subjects will be evaluated by alternative answer or free description. 1) Patietn types in which safinamide should be used from the viewpoints of motor symptoms, motor complications, non-motor symptoms, treatment history, etc. associated with Parkinson's disease 2) Patient types in which safinamide should be withheld, reduced dose or discontinued 3) Use method when dyskinesia appears while using safinamide, optimal safinamide use method for the elderly, and patient types where it is recommended to increase the safinamide dose to a high dose. 4) Demographic profiles of subjects	—

Measure

Time frame

The following items are evaluated on a four-point scale: 1 (disagree), 2 (somewhat disagree), 3 (somewhat agree), and 4 (agree). For some questions, the perspective of the subjects will be evaluated by alternative answer or free description. 1) Patietn types in which safinamide should be used from the viewpoints of motor symptoms, motor complications, non-motor symptoms, treatment history, etc. associated with Parkinson's disease 2) Patient types in which safinamide should be withheld, reduced dose or discontinued 3) Use method when dyskinesia appears while using safinamide, optimal safinamide use method for the elderly, and patient types where it is recommended to increase the safinamide dose to a high dose. 4) Demographic profiles of subjects

—

Countries

Japan

Contacts

Public ContactTakayuki Ishida

Eisai Co., Ltd. Medical HQs

t8-ishida@hhc.eisai.co.jp03-5228-7112

Outcome results